Nabriva Therapeutics AG (NASDAQ:NBRV) CFO Gary Sender purchased 2,000 shares of the business’s stock in a transaction on Friday, September 22nd. The shares were acquired at an average price of $8.21 per share, for a total transaction of $16,420.00. Following the completion of the acquisition, the chief financial officer now directly owns 4,200 shares in the company, valued at approximately $34,482. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Nabriva Therapeutics AG (NASDAQ NBRV) opened at 8.35 on Thursday. The stock’s 50 day moving average price is $9.01 and its 200-day moving average price is $10.19. The firm’s market capitalization is $224.10 million. Nabriva Therapeutics AG has a 12 month low of $3.52 and a 12 month high of $14.10.

Nabriva Therapeutics AG (NASDAQ:NBRV) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($5.83) by $5.29. The firm had revenue of $1.05 million for the quarter, compared to the consensus estimate of $1.34 million. Equities analysts anticipate that Nabriva Therapeutics AG will post ($2.29) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/28/gary-sender-purchases-2000-shares-of-nabriva-therapeutics-ag-nbrv-stock.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors boosted its position in shares of Nabriva Therapeutics AG by 4.6% during the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after purchasing an additional 7,924 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Nabriva Therapeutics AG by 19.6% during the second quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after purchasing an additional 8,650 shares in the last quarter. Almanack Investment Partners LLC. bought a new stake in shares of Nabriva Therapeutics AG during the first quarter valued at approximately $1,870,000. Finally, Wellington Management Group LLP boosted its position in shares of Nabriva Therapeutics AG by 9.9% during the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after purchasing an additional 193,951 shares in the last quarter. Institutional investors own 67.60% of the company’s stock.

A number of equities analysts have issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $18.00 price target (up from $15.00) on shares of Nabriva Therapeutics AG in a report on Tuesday, September 19th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Nabriva Therapeutics AG in a report on Tuesday, September 19th. Wedbush restated an “outperform” rating and set a $21.00 price target (up from $13.00) on shares of Nabriva Therapeutics AG in a report on Monday, September 18th. Leerink Swann restated an “outperform” rating and set a $22.00 price target (up from $20.00) on shares of Nabriva Therapeutics AG in a report on Monday, September 18th. Finally, SunTrust Banks, Inc. increased their price target on Nabriva Therapeutics AG from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, September 18th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $19.13.

About Nabriva Therapeutics AG

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Insider Buying and Selling by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.